Source:http://linkedlifedata.com/resource/pubmed/id/12802925
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2003-6-13
|
| pubmed:abstractText |
We established and characterized a c-kit positive cell line from the bone marrow of a patient with biphenotypic acute leukemia (BAL). The cell line, designated TMBL-1, carried a His-175 mutant p53. The immunophenotype of the primary leukemia cells at diagnosis was cytoplasmic CD3+, CD7+, CD13+, CD33-, interleukin-7 (IL-7) receptor+ and c-kit -. However, leukemia cells in relapse and TMBL-1 cells were CD33+ and c-kit +. Immunophenotypically, TMBL-1 is a BAL cell line that coexpresses T-lymphoid and myeloid markers which fulfill the criteria of the European Group for the Immunological Characterization of Leukemia. Stem cell factor (SCF), a key regulator of hematopoiesis signaling through c-kit, enhanced the proliferation of TMBL-1 cells. Direct sequencing revealed the conversion at codon 175 of the p53 gene in the TMBL-1 cells. Primary leukemia cells in relapse also carried the same point mutation but not at diagnosis. Moreover, TMBL-1 cells are sensitive to paclitaxel, which could induce p53-independent apoptosis. The biphenotypic features and p53 mutation may be associated with progression to a more malignant type. This cell line may provide new information on the role of SCF in the overlapping area between early T-lymphoid/myeloid cells, and help in the design of new therapies targeted towards p53 mutations.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
1042-8194
|
| pubmed:author |
pubmed-author:ArimaTerukatsuT,
pubmed-author:HanadaShuichiS,
pubmed-author:LinXiao-YanXY,
pubmed-author:OhnoNobuhitoN,
pubmed-author:OwatariSatsukiS,
pubmed-author:SuzukiShinsukeS,
pubmed-author:TakatsukaYoshifusaY,
pubmed-author:TakeshitaTaketsuguT,
pubmed-author:TakeuchiSyogoS,
pubmed-author:UozumiKimiharuK
|
| pubmed:issnType |
Print
|
| pubmed:volume |
44
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
849-57
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:12802925-Adult,
pubmed-meshheading:12802925-Bone Marrow Cells,
pubmed-meshheading:12802925-Cell Division,
pubmed-meshheading:12802925-Humans,
pubmed-meshheading:12802925-Immunophenotyping,
pubmed-meshheading:12802925-Leukemia,
pubmed-meshheading:12802925-Male,
pubmed-meshheading:12802925-Myeloid Cells,
pubmed-meshheading:12802925-Paclitaxel,
pubmed-meshheading:12802925-Point Mutation,
pubmed-meshheading:12802925-Proto-Oncogene Proteins c-kit,
pubmed-meshheading:12802925-Stem Cell Factor,
pubmed-meshheading:12802925-T-Lymphocytes,
pubmed-meshheading:12802925-Tumor Cells, Cultured,
pubmed-meshheading:12802925-Tumor Suppressor Protein p53
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
A novel c-kit positive biphenotypic acute leukemia cell line, TMBL-1, carrying a p53 point mutation.
|
| pubmed:affiliation |
Second Department of Internal Medicine, Faculty of Medicine, Kagoshima University, National Hospital, Kyushu Cardiovascular Center, Kagoshima, Japan. suzuki2@med2.kufm.kagoshima-u.ac.jp
|
| pubmed:publicationType |
Journal Article
|